FibroGen adds to selloff, down 5% on bearish report

Embattled FibroGen (FGEN -4.5%) is down again today on a 4x surge in volume, adding to longs’ misery after yesterday’s 15% drop.

Muddy Waters Research added fuel to roxadustat safety profile-stoked worries with a short report published today on BuyersStrike that asserted the company under-reported deaths in a late-stage study.

Related ticker: AstraZeneca (AZN +0.6%)

https://seekingalpha.com/news/3518178-fibrogen-adds-selloff-5-percent-bearish-muddy-waters-report